Advertisement
Singapore markets closed

  • Straits Times Index

    3,331.70
    +5.42 (+0.16%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • Dow

    39,112.16
    -299.05 (-0.76%)
     

  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     

  • Bitcoin USD

    61,325.16
    +48.39 (+0.08%)
     

  • CMC Crypto 200

    1,274.42
    -9.37 (-0.73%)
     

  • FTSE 100

    8,274.96
    +27.17 (+0.33%)
     

  • Gold

    2,329.00
    -1.80 (-0.08%)
     

  • Crude Oil

    81.57
    +0.74 (+0.92%)
     

  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     

  • Nikkei

    39,667.07
    +493.92 (+1.26%)
     

  • Hang Seng

    18,089.93
    +17.03 (+0.09%)
     

  • FTSE Bursa Malaysia

    1,590.95
    +5.57 (+0.35%)
     

  • Jakarta Composite Index

    6,905.64
    +22.94 (+0.33%)
     

  • PSE Index

    6,313.11
    +14.06 (+0.22%)
     

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

EyePoint Pharmaceuticals, Inc.
·2-min read
EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.

WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 3:20 p.m. ET.

A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU (previously known as EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

ADVERTISEMENT

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com